ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2391

Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1866

Identification of Sjögren’s Disease-Associated CD4+ T Cell Receptor (TCR) Motifs and Repertoire Landscape Through TCR Deep Sequencing

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 2211

Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 1971

Identifying Educational Opportunities Through Examination of Referrals to Rheumatology Musculoskeletal US Clinic

Imaging of Rheumatic Diseases Poster II

10:30AM-12:30PM: Abstract Number: 2196

Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2507

IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

10:30AM-12:30PM: Abstract Number: 2119

IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 1983

Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review

Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1833

Immune Complexes of Antibodies Directed to Angiotensin Receptor type-1 and Extracellular Vesicles Are Unique Modulators Contributing to Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster II

10:30AM-12:30PM: Abstract Number: 1795

Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 1843

Immune Responses to Herpes Zoster Vaccine Responses in Rheumatic Patients on JAK Inhibitors: Insights in Humoral and Cellular Response

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 2201

Immunodeficiency-Related Monogenic Autoinflammatory Diseases; Expanding Spectrum of Immunodysregulation Disorders

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2266

Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis

RA – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2005

Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 2369

Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis

SpA Including PsA – Treatment Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].